Switch theme
Sign up to access all valuation multiples
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
2014
506
LTM Revenue $138M
LTM EBITDA -$79.4M
-$17.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Adaptimmune Therapeutics has a last 12-month revenue of $138M and a last 12-month EBITDA of -$79.4M.
In the most recent fiscal year, Adaptimmune Therapeutics achieved revenue of $178M and an EBITDA of -$52.7M.
Adaptimmune Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Adaptimmune Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $60.3M | $178M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$128M | -$52.7M | XXX | XXX | XXX |
| EBITDA Margin | -213% | -30% | XXX | XXX | XXX |
| Net Profit | -$165M | -$114M | XXX | XXX | XXX |
| Net Margin | -274% | -64% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Adaptimmune Therapeutics's stock price is $0.
Adaptimmune Therapeutics has current market cap of $60.2M, and EV of -$17.2M.
See Adaptimmune Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$17.2M | $60.2M | XXX | XXX | XXX | XXX | $-0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Adaptimmune Therapeutics has market cap of $60.2M and EV of -$17.2M.
Adaptimmune Therapeutics's trades at -0.1x LTM EV/Revenue multiple, and 0.2x LTM EBITDA.
Analysts estimate Adaptimmune Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Adaptimmune Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$17.2M | XXX | XXX | XXX |
| EV/Revenue | -0.1x | XXX | XXX | XXX |
| EV/EBITDA | 0.3x | XXX | XXX | XXX |
| P/E | -0.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAdaptimmune Therapeutics's NTM/LTM revenue growth is -65%
Adaptimmune Therapeutics's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.5M for the same period.
Over next 12 months, Adaptimmune Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Adaptimmune Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Adaptimmune Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 195% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -30% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -59% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -95% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 45% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 84% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 129% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Adaptimmune Therapeutics acquired XXX companies to date.
Last acquisition by Adaptimmune Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Adaptimmune Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Adaptimmune Therapeutics founded? | Adaptimmune Therapeutics was founded in 2014. |
| Where is Adaptimmune Therapeutics headquartered? | Adaptimmune Therapeutics is headquartered in United States of America. |
| How many employees does Adaptimmune Therapeutics have? | As of today, Adaptimmune Therapeutics has 506 employees. |
| Who is the CEO of Adaptimmune Therapeutics? | Adaptimmune Therapeutics's CEO is Mr. Adrian Rawcliffe. |
| Is Adaptimmune Therapeutics publicy listed? | Yes, Adaptimmune Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Adaptimmune Therapeutics? | Adaptimmune Therapeutics trades under ADAP ticker. |
| When did Adaptimmune Therapeutics go public? | Adaptimmune Therapeutics went public in 2015. |
| Who are competitors of Adaptimmune Therapeutics? | Similar companies to Adaptimmune Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Adaptimmune Therapeutics? | Adaptimmune Therapeutics's current market cap is $60.2M |
| What is the current revenue of Adaptimmune Therapeutics? | Adaptimmune Therapeutics's last 12-month revenue is $138M. |
| What is the current EBITDA of Adaptimmune Therapeutics? | Adaptimmune Therapeutics's last 12-month EBITDA is -$79.4M. |
| What is the current EV/Revenue multiple of Adaptimmune Therapeutics? | Current revenue multiple of Adaptimmune Therapeutics is -0.1x. |
| What is the current EV/EBITDA multiple of Adaptimmune Therapeutics? | Current EBITDA multiple of Adaptimmune Therapeutics is 0.2x. |
| What is the current revenue growth of Adaptimmune Therapeutics? | Adaptimmune Therapeutics revenue growth between 2023 and 2024 was 195%. |
| Is Adaptimmune Therapeutics profitable? | Yes, Adaptimmune Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
